The global Acute Repetitive Seizures Market size is expected
to reach USD 3.19 billion by 2025, according to a new report by Grand View
Research, Inc. The report also states that the market will expand at a strong
CAGR of 47.8% during the forecast period. Rise in the number of initiatives to
increase the awareness about epilepsy is the major factor driving the market.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
The market is currently led by generic drugs which mainly
include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the
only approved drug for use in U.S. and buccal midazolam in European Union.
Other drugs, such as diazepam (oral and intramuscular), midazolam (buccal,
intranasal, intramuscular), lorazepam (oral, intranasal, sublingual), and
progesterone are majorly used off label. The market is expected to be
consolidated with few major companies and high market share.
Furthermore, in an attempt to curb healthcare
expenditure, governments are making continuous efforts to reduce hospital stays
and on-site treatment costs via outpatient care models, such as clinic and home
healthcare. Emerging economies like India and China, are increasingly implementing
such healthcare reform, which is expected to propel the growth of acute
repetitive seizures market.
There are several routes of drug administration; out of
which, nasal route is the most preferred over others, such as buccal, rectal,
and parenteral. The buccal route is preferred by caregivers and parents for
children suffering from pediatric seizures since medication can be administered
even outside the hospital.
Browse Details of Report @
https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market
https://www.grandviewresearch.com/industry-analysis/acute-repetitive-seizures-market
Further key findings from the study
suggest:
- Global
acute repetitive seizures market size was estimated at USD 140.5 million
in 2017 and is expected to register a CAGR of 47.8% over the forecast
period
- Diastat
rectal gel was the dominant product segment in 2017 due to efficacy of the
route of administration and affordability of the product
- USL-261 is
expected to witness a lucrative CAGR over the forecast period. USL-21 has
an edge over the other drugs owing to its superior clinical profile and
positive phase III results
- North
America held the largest share in 2017 due to factors, such as growing
initiatives for raising awareness about epilepsy and seizures
- Germany is
anticipated to witness lucrative growth over the next decade owing to
technological advancements in scientific, clinical, and medical fields
- Some of
the key companies in the market are UCB S.A.; Neurelis, Inc.; and Alexza
Pharmaceuticals, Inc. These companies are likely to dominate the market
and gain maximum share over the forecast period
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment